Anti-angiogenic Agents in Resectable Colorectal Cancer Metastases: A Lebanese ExperienceAntoine Abi Abboud*, Evelyne Helou, Rim Ismail and Layale Olaywan
Department of Internal Medicine, Faculty of Medical Sciences, Lebanese University, Lebanon
- *Corresponding Author:
- Antoine Abi Abboud
Medicine Division of Gastroenterology
Faculty of Medical Sciences, Lebanese University
Email: [email protected]
Received date: June 08, 2017; Accepted date: June 27, 2017; Published date: June 30, 2017
Citation: Abboud AA, Helou E, Ismail R, Olaywan L (2017) Anti-angiogenic Agents in Resectable Colorectal Cancer Metastases: A Lebanese Experience. J Gastrointest Dig Syst 7:513. doi:10.4172/2161-069X.1000513
Copyright: © 2017 Abboud AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Certain studies demonstrated that the addition of anti-VEGF and anti-EGFR drugs improves the overall survival, progression free survival, and response rate in colorectal cancer patients after resection of their liver metastases in a curative intent. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colorectal liver metastases.
Methods: In this research, 11 patients with colorectal cancer and potentially curative liver metastases, who underwent metastasectomy from different Lebanese hospitals were analyzed. Patients received 5-FU, irinotecan, oxaliplatin with either cetuximab or bevacizumab pre and post operation. Response rate was compared between patients retrospectively, whether complete, partial, stable, or no response.
Results: Out of 11 patients, 5 patients had progression free survival for 3 months after surgery, out of which 1 (9%) had a complete response, 2 had partial response, and 2 had a stable disease. No increase in the major side effects or mortality was noted.
Discussion: Our results agree with other studies from different geographic regions. We recommend the addition of a biological agent to the standard systemic chemotherapy, because it is associated with improved overall survival and disease control rate, but further studies are still needed to investigate the influence of KRAS and BRAF mutation status on prognosis and treatment outcome.